Back to top
more

Inari Medical (NARI)

(Delayed Data from NSDQ)

$57.98 USD

57.98
972,472

+3.18 (5.80%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $58.68 +0.70 (1.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (155 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Inari Medical (NARI) Reports Solid Preliminary Q4 Revenues

Inari Medical's (NARI) revenue growth in the fourth quarter is likely to have been boosted by continued demand for its products, market expansion and new launches.

Strength Seen in Inari Medical, Inc. (NARI): Can Its 5.6% Jump Turn into More Strength?

Inari Medical, Inc. (NARI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.

Inari Medical (NARI) Q3 Earnings Beat, Revenues Rise Y/Y

Inari Medical's (NARI) third-quarter results benefit from significant progress made across all its growth drivers.

Inari Medical, Inc. (NARI) Reports Q3 Loss, Tops Revenue Estimates

Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 20.83% and 6.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Alphatec (ATEC) Report Negative Earnings Next Week? What You Should Know

Alphatec (ATEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Inari Medical, Inc. (NARI) Q3 Earnings Expected to Decline

Inari Medical, Inc. (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.

Inari Medical (NARI) Posts Positive Results of FLASH Registry

Inari Medical's (NARI) FlowTriever's latest favorable results are expected to significantly improve the treatment of PE.

Inari Medical, Inc. (NARI) Down 16.4% Since Last Earnings Report: Can It Rebound?

Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.

Inari Medical (NARI) Q2 Earnings Beat, CEO Transition in 2023

Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.

Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates

Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 17.39% and 5.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Steris (STE) Meets Q1 Earnings Estimates

Steris (STE) delivered earnings and revenue surprises of 0% and 5.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Alphatec (ATEC) to Report a Decline in Earnings: What to Look Out for

Alphatec (ATEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thermo Fisher Scientific (TMO) Q2 Earnings and Revenues Top Estimates

Thermo Fisher (TMO) delivered earnings and revenue surprises of 11.99% and 11.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: Should You Buy?

Inari Medical, Inc. (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

Inari Medical (NARI) continues to benefit from its commitment toward understanding the venous system. However, dependency on the wide adoption of products is a woe.

Inari Medical (NARI) Down 16.9% Despite Q1 Earnings Beat

Inari Medical's (NARI) first-quarter results benefit from significant progress made across all of its growth drivers.

Inari Medical, Inc. (NARI) Reports Q1 Loss, Tops Revenue Estimates

Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 25% and 4.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Inari Medical, Inc. (NARI): Can Its 6.2% Jump Turn into More Strength?

Inari Medical, Inc. (NARI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Inari Medical, Inc. (NARI) Up 2% Since Last Earnings Report: Can It Continue?

Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Inari Medical (NARI) Gains 12.5% Despite In-Line Q4 Earnings

Inari Medical's (NARI) fourth-quarter results benefit from significant progress made across all of its growth drivers.

Inari Medical (NARI) Posts Solid Preliminary Q4, FY2021 Revenues

Inari Medical (NARI) posts solid fourth-quarter and full-year 2021 revenue data, courtesy of resilience shown in the face of the COVID-19 induced challenges.

New Strong Sell Stocks for November 10th

AZN, GOLD, NARI, KOP, and TCEHY have been added to the Zacks Rank #5 (Strong Sell) List on November 10, 2021.